Metacartin solution for injection

All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"
Application of the infusion form of L-carnitine in the complex treatment of patients with stage III chronic kidney disease
Published in the journal «Medical Business» № 1-2’2018
Mitochondrial dysfunction in neurodegenerative disorders: from pathogenesis to therapy
Published in a journal «International Journal of Neurology» Vol 16 № 4’2020
Aspects of the use of metabolic therapy in patients with cognitive impairment in post-COVID syndrome
Published in the medical newspaper «Health of Ukraine 21st century» № 18 (511)’2021
Based on the neuro-COVID trilogy
Published in the medical newspaper «Health of Ukraine of the 21st century» № 22 (515)’2021
The role of carnitine in the regulation of energy metabolism and modulation of the course of cardiovascular diseases and diabetes mellitus
Published in a journal «Hypertension» Vol 13 № 2 ’2020
Preventing heart failure and improving prognosis in patients after primary transcutaneous angioplasty by adding L-carnitine in acute myocardial infarction
Published in the journal «Cardiology: from science to practice» № 3 (37) ’2019
Effect of L-carnitine on the lipid profile of patients with coronary artery disease
Published in thematic issue «Cardiology, Rheumatology, Cardiac Surgery» № 1 (50) ’2017
Correction of secondary carnitine deficiency in chronic hemodialysis patients: focus on levocarnitine
Published in the journal «Kidneys» № 1 (19) ’2017

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design